ESID Congress - Octapharma Symposium

Recent Insights and Clinical Approaches in the Management of Antibody Deficiencies

Share this page


Recent Insights and Clinical Approaches in the Management of Antibody Deficiencies

Friday, 14 October 2022

12:15 - 13:45 CEST

Session Hall 1, Svenska Mässan Gothia Towers | Gothenburg, Sweden

Summary of the session

While primary antibody deficiencies (PAD) are the result of genetic defects, secondary antibody deficiencies (SAD) are more prevalent and are the consequence of an underlying condition or medication use.

Recently, rituximab has provided clinical proof of concept that targeting B-cells results in a significant benefit to patients with a deregulated B-cell function in autoimmune diseases or haematological malignancies. Consequently, the interest in B-cell targeted therapies has increased and biologics with different targets have been developed. However, these therapies potentially cause iatrogenic hypogammaglobulinaemia and are associated with increased risk of infection.

Lymphoma and immunodeficiencies are closely linked. Malignancy and especially lymphoma is the second most prevalent cause of death after infection in PID. The wide use of R-CHOP contributes to the high frequency of hypogammaglobulinemia and increased mortality due to infections. Monitoring immunoglobulin levels may allow for earlier identification of risk and patients who may benefit from immunoglobulin replacement therapy (IgRT).

The standard of care for PAD and SAD is IgRT administered intravenously or subcutaneously. There are distinct clinical advantages to subcutaneous administration such as stable serum IgG levels, fewer systemic side effects and high tolerability combined with flexibility of home treatment. Recent clinical data and long-term experience will be discussed during the session.


Symposium programme



Welcome and introduction

Chair: Isabella Quinti (Rome, Italy)

Evaluating and managing the increased patient risk of serious infections following B-cell targeted therapies

Elie Haddad (Montreal, Canada)

The complex relationship between immunodeficiencies and lymphoma

Fabrizio Vianello (Padova, Italy)

Optimising patient outcomes by leveraging recent clinical data and long term experience

Roger H. Kobayashi (Omaha, Nebraska, USA)




Isabella Quinti (Rome, Italy)

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.

Speakers panel

Chair: Isabella Quinti

Sapienza University of Rome, Italy

Elie Haddad

Sainte-Justine University

Hospital, Montreal, Canada

Fabrizio Vianello

University of Padova, Italy

Roger H. Kobayashi

Omaha, Nebraska, USA

UCLA School of Medicine, USA

To attend this Octapharma Symposium, register to the ESID 2022 Congress

Share this page


Register to Science Hub

Visit our platform for HCPs to explore events, on demand lectures, clinical trials, educational resources and more.

Visit our website to learn more about SID

"Secondary immunodeficiencies have been a major concern in hematological malignancies. We need to remain very careful with the risk of infection.", says Dr. Anne Quinquenel (Reims, France).